Mediastinal gray zone lymphoma

Quintanilla-Martı́nez, Leticia; Fend, Falko

doi:10.3324/haematol.2011.043026

Cited by 27 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fifty-five patients (55%) had Ann Arbor stage III-IV disease, 40 had stage II, and 4 had stage I. Anemia (<10.5 g/dL) was present in 21% of the patients and lymphopenia (<600/mm 3 ) was present in 34%. The erythrocyte sedimentation rate (ESR) was elevated in 68% and the albumin level was low (<35 g/L) in 39%.…”

Section: Clinical and Biological Characteristicsmentioning

confidence: 99%

“…During the first meeting in the LYSA-P, the panel of 12 hematopathologists (ATG, TM, DD, PD, BF, CL, MP, LM, DC, BB, PG, CC) established a consensus for inclusion criteria based on previous pathological descriptions of MGZL from the literature. [2][3][4][5]9 They identified 4 situations or subgroups, which are presented in the results section, and in Table 1 and Figure 1, to analyze patients' characteristics and outcomes. As a second step, the panel reviewed all the cases with a multi-head microscope during 3 meetings.…”

Section: Pathological Definition Of Mgzl and Inclusion Criteriamentioning

confidence: 99%

“…[2][3][4][5] Although more recent publications defined a particular methylation profile for this entity, 6,7 and a particular immunohistochemistry scoring system to distinguish it from CHL and PMBCL, 8 there is a need for clarification of the clinico-pathological diagnostic criteria for MGZL. Previous retrospective studies 4,5,[9][10][11][12] (including from 2 to 112 cases) showed that patients with an MGZL had a poorer outcome than patients with a PMBCL or diffuse large B-cell lymphoma (DLBCL).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

et al. 2016

View full text Add to dashboard Cite

Mediastinal gray zone lymphoma, B-cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma, have not been well described in the literature. We report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis. Cases were defined as classical Hodgkin lymphoma-like morphology (64.6%) with primary mediastinal B-cell lymphoma immunophenotype, primary mediastinal B-cell lymphoma-like morphology (30.3%) with classical Hodgkin lymphoma or composite (5.1%) (synchronous occurrence of classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma). The median age was 32 years (13-83 years); 55% were women. Thirteen of 81 evaluable cases (16%) were Epstein-Barr virus-positive. Twenty-eight percent of patients presented primary refractory disease (progression under first-line treatment or relapse within one year). The 3-year event-free and overall survival rates were 63% and 80%, respectively. Patients treated with a standard regimen (RCHOP/ABVD) had worse event-free survival (P=0.003) and overall survival (P=0.02) than those treated with a dose-intensive chemotherapy (high-dose RCHOP/escalated BEACOPP). Rituximab added to chemotherapy was not associated with better event-free survival (P=0.55) or overall survival (P=0.88). Radiotherapy for patients in complete remission had no impact on eventfree survival. In multivariate prognostic analysis, ECOG-PS and anemia were the strongest factors associated with a shorter event-free survival and overall survival, respectively. In conclusion, this report describes the largest series of mediastinal gray zone lymphoma. Our data suggest that a dose-intensive treatment might improve the outcome of this rare and aggressive disease.

show abstract

Section: Clinical and Biological Characteristicsmentioning

confidence: 99%

Section: Pathological Definition Of Mgzl and Inclusion Criteriamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

et al. 2016

View full text Add to dashboard Cite

show abstract

“…61,62 Together with more recent genetic and epigenetic studies, they also support the inclusion in the WHO classification of the category large B-cell lymphoma, unclassifiable with features intermediate between DLBCL and HL. [63][64][65][66] …”

Section: Characterization Of Known Entities and Recognition Of New Camentioning

confidence: 99%

Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes

Campo

2013

Modern Pathology

View full text Add to dashboard Cite

The development of high throughput technologies based on the knowledge of the human genome has opened the possibility to search for global genomic alterations in tumors responsible for their development and progression that may have important clinical implications. One of the major applications of this genomic knowledge has been the design of different types of microarray platforms for the analysis of DNA alterations and gene expression profiling (GEP). The main contributions of the DNA studies in lymphoid neoplasms include the definition of relatively characteristic genomic profiles for specific disease entities, the demonstration of common chromosomal alterations across entities, the identification of genes and pathways targeted by the altered chromosomal regions, and the identification of chromosomal alterations with prognostic implications. RNA GEP studies in these tumors have enhanced the molecular characterization of known entities and facilitated the recognition of new subtypes and categories of lymphoid neoplasms, the identification of new biomarkers and prognostic models, and the detection of oncogenic pathways with potential implications for targeted therapies. The recent development of the next generation sequencing (NGS) technologies and its application in lymphoid neoplasms already have provided an initial view of the complex landscape of somatic mutations in these tumors and some findings with important functional and clinical implications. This review addresses the major contributions and limitations of the microarray technologies in the understanding of lymphoid neoplasms and discusses how this knowledge may be transferred into the clinics. The initial results of the NGS studies are also presented.

show abstract

“…MGZL denotes cases with transitional features between cHL and primary mediastinal large B-cell lymphoma (PMBL) [23,24] and generally have a poorer outcome. A composite lymphoma of cHL and PMBL, a phenomenon that may be related to MGZLs also remained a consideration [9].…”

mentioning

confidence: 99%

An unusual patient with shortness of breath—Clinical, radiologic, and pathologic pitfalls

et al. 2014

View full text Add to dashboard Cite

Mediastinal gray zone lymphoma

Cited by 27 publications

References 15 publications

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association

Whole genome profiling and other high throughput technologies in lymphoid neoplasms—current contributions and future hopes

An unusual patient with shortness of breath—Clinical, radiologic, and pathologic pitfalls

Contact Info

Product

Resources

About